Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success tags : Bioscience save search
Adimab Announces Successful Resolution of Lawsuit Brought Against LinkedUp Bioscience and Tianti Biotherapeutics
Published: 2023-12-21 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
bioscience
DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience
Published: 2023-01-05 (Crawled : 19:00) - biospace.com/
HHLA | $10.75 0.0% 0
|
|
| O: 0.1%
H: 0.1%
C: 0.05%
oncuria bioscience study
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Published: 2022-03-23 (Crawled : 09:00) - prnewswire.com
APVO 4 d | $0.721 -6.36% -6.8% 230K
|
Health Technology
|
| O: -0.19%
H: 4.42%
C: 0.77%
mitazalimab trial bioscience enroll
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Published: 2022-03-14 (Crawled : 11:00) - globenewswire.com
DRUG | $1.25 -6.61% 11K
|
Manufacturing
|
| O: 11.83%
H: 1.13%
C: -12.43%
day trial success bioscience
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate
Published: 2022-02-08 (Crawled : 13:00) - prnewswire.com
ENVB | $0.8989 -4.17% -4.35% 130K
|
Health Technology
|
| O: 6.88%
H: 2.48%
C: -3.28%
ev104 ces patent cel success bioscience
Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Published: 2022-01-04 (Crawled : 19:00) - biospace.com/
ENSC | News | $0.561 -3.31% -3.42% 190K
|
Health Technology
|
| O: 4.43%
H: 4.23%
C: -8.93%
pf614 trial opioid bioscience
Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
EVFM | $0.0141 -16.94% 180K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
fda bioscience
Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023
Published: 2021-11-22 (Crawled : 12:00) - prnewswire.com
EVFM | $0.0141 -16.94% 180K
|
Health Technology
|
| O: 8.89%
H: 2.29%
C: -1.8%
sales bioscience
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.